{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:04:01Z","timestamp":1772183041212,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcpo.2025.100613","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:33:51Z","timestamp":1751916831000},"page":"100613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Budget impact analysis of treatment-free remission in chronic myeloid leukemia patients treated with nilotinib in Tunisia"],"prefix":"10.1016","volume":"45","author":[{"given":"Aziz","family":"Hizem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Keskes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajer","family":"Felfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcpo.2025.100613_bib1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"_4","key":"10.1016\/j.jcpo.2025.100613_bib2","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.jcpo.2025.100613_bib3","first-page":"229","article-title":"Molecular monitoring of Tunisian patients with chronic myeloid leukemia","volume":"95","author":"Menif","year":"2017","journal-title":"Tunis. Med"},{"issue":"1","key":"10.1016\/j.jcpo.2025.100613_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 - common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jcpo.2025.100613_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"issue":"5","key":"10.1016\/j.jcpo.2025.100613_bib7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcpo.2025.100613_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J. Blood Med"},{"issue":"6","key":"10.1016\/j.jcpo.2025.100613_bib9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","article-title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","volume":"35","author":"Hughes","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jcpo.2025.100613_bib10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jcpo.2025.100613_bib11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jcpo.2025.100613_bib12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jval.2020.11.010","article-title":"Budget impact of tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia with sustained deep molecular response","volume":"24","author":"Astrugue","year":"2021","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jcpo.2025.100613_bib13","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1111\/cas.14430","article-title":"Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients","volume":"111","author":"Yamazaki","year":"2020","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.jcpo.2025.100613_bib14","first-page":"1","article-title":"Budget impact of treatment-free remission in treating chronic-phase Philadelphia-positive chronic myeloid leukemia in Lebanon","author":"Elias","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.jcpo.2025.100613_bib15","doi-asserted-by":"crossref","unstructured":"Mennini F., Marcellusi A., Viti R., Saglio G. Budget Impact analysis of the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) adult patients, Farmeconomia Health Economics and Therapeutic Pathways (Internet) 2017 Jul 28, 18(1). (Accessed 5 December 2024). \u3008https:\/\/journals.seedmedicalpublishers.com\/index.php\/FE\/article\/view\/1318\u3009.","DOI":"10.7175\/fe.v18i1.1318"},{"issue":"1","key":"10.1016\/j.jcpo.2025.100613_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jcpo.2025.100613_bib17","unstructured":"Choix Methodologiques Pour L\u2019analyse De L\u2019impact Budgetaire a l\u2019ineas \/ Ineas (Internet). Instance Nationale de l\u2019\u00c9valuation et de l\u2019Accr\u00e9ditation en Sant\u00e9, Tunis, 2021. (Accessed 5 December 2024. \u3008http:\/\/portail.ineas.tn\/Default\/doc\/SYRACUSE\/1151\/choix-methodologiques-pour-l-analyse-de-l-impact-budgetaire-a-l-ineas-ineas\u3009."},{"issue":"5","key":"10.1016\/j.jcpo.2025.100613_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","article-title":"Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib","volume":"124","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jcpo.2025.100613_bib20","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"Experts in Chronic Myeloid Leukemia, The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts","volume":"121","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcpo.2025.100613_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11864-021-00851-2","article-title":"When to stop TKIs in patients with chronic myeloid leukemia and how to follow them subsequently","volume":"22","author":"Cerveira","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"issue":"5","key":"10.1016\/j.jcpo.2025.100613_bib23","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.18883","article-title":"Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: final 5-year analysis of DASFREE","volume":"202","author":"Shah","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jcpo.2025.100613_bib24","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/S2152-2650(21)01783-3","article-title":"CML-405: treatment-free remission in chronic myeloid leukemia: a Tunisian experience","volume":"21","author":"Frikha","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.jcpo.2025.100613_bib25","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1182\/blood-2018-99-119200","article-title":"Impact of treatment free remission (TFR) with nilotinib in 2nD Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL tests in the Brazilian public healthcare system during and after nilotinib treatment","volume":"132","author":"Abdo","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jcpo.2025.100613_bib26","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood.V126.23.3293.3293","article-title":"Pharmacoeconomical analysis of chronic myelogenous leukemia treatment free remission","volume":"126","author":"Shuvaev","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcpo.2025.100613_bib28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40273-017-0602-5","article-title":"The French National Authority for Health (HAS) guidelines for conducting budget impact analyses (BIA)","volume":"36","author":"Ghabri","year":"2018","journal-title":"PharmacoEconomics"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:20:35Z","timestamp":1772180435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538325000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"alternative-id":["S2213538325000578"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100613","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budget impact analysis of treatment-free remission in chronic myeloid leukemia patients treated with nilotinib in Tunisia","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100613"}}